Our Latest

Nov 8, 2022 MINNEAPOLIS – November 8, 2022 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that the International Society for the Advancement of Spine Surgery (ISASS) has published an updated Policy Statement and Literature Review of Intraosseous Basivertebral Nerve […]

Results from Multiple Clinical Trials Demonstrate the Intracept Procedure is: Safe Strong safety profile with less than 0.3% rate of serious Intracept Procedure-related complications reported across nearly 400 clinical trial patients. 1 Effective Two Level I RCTs demonstrate that the Intracept Procedure is an effective treatment compared to both a sham-control procedure and to non-surgical standard […]

February 14, 2022 Findings from Cleerly’s groundbreaking echo the recent American College of Cardiology guidelines on the use of CCTA for non-invasive heart disease evaluation. Instead of proactively identifying patients at risk of heart disease, our industry has historically treated patients once symptoms appear, which can result in late or missed diagnoses, as well as […]

James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: January 28, 2022 Historically, our diagnostic approaches to patients with suspected heart disease have been restricted to the evaluation of patients with symptoms like chest pain and shortness of breath. Yet, these diagnostic methods fail for the >50% of individuals who will suffer […]

The Background To confirm that a patient has vertebrogenic pain, physicians use MRI to look for specific changes that occur with endplate inflammation, which are called Modic changes. They’re called “Modic changes” because in 1988, Dr. Michael Modic was the first to publish on identifying and classifying degenerative endplate and marrow changes surrounding a dehydrated […]

September 27, 2021 MINNEAPOLIS & WASHINGTON, DC—(BUSINESS WIRE)—Vensana Capital today announced the closing of its second fund, Vensana Capital II, with $325 million in committed capital. The fund was oversubscribed at its hard cap with the support of the firm’s investors in its inaugural fund alongside select new institutional investors. Vensana Capital launched in 2019 […]

Vensana Capital, a medical technology-focused venture capital firm based in Minneapolis and Washington, DC, is submitting this letter in response to the interim final rule delaying the effective date and requesting additional comment on the final rule establishing the MCIT coverage pathway for Food and Drug Administration (FDA)- designated breakthrough medical devices (“Notice of Delay”).1 […]

VC Policy Pulse: Medical Device Coverage Reform with Vensana’s Justin Klein & Kirk Nielsen MARCH 30, 2021/BY DEVIN MILLER Welcome to our VC Policy Pulse series, where we speak with VC investors on policy issues that are having a major impact on the VC and startup ecosystem. Today, we’re hearing from Justin Klein and Kirk Nielsen, […]

TEDCO’s annual Entrepreneur Expo was established to spotlight entrepreneurship in the region by bringing together Maryland’s various resources for a day of celebration.